Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) EBIT (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed EBIT for 16 consecutive years, with $61.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT fell 1.59% year-over-year to $61.8 million, compared with a TTM value of $257.8 million through Dec 2025, up 32.11%, and an annual FY2025 reading of $257.8 million, up 32.11% over the prior year.
  • EBIT was $61.8 million for Q4 2025 at Catalyst Pharmaceuticals, down from $66.3 million in the prior quarter.
  • Across five years, EBIT topped out at $66.3 million in Q2 2025 and bottomed at -$37.2 million in Q3 2023.
  • Average EBIT over 5 years is $34.7 million, with a median of $33.2 million recorded in 2022.
  • The sharpest move saw EBIT tumbled 248.15% in 2023, then surged 236.9% in 2024.
  • Year by year, EBIT stood at $12.7 million in 2021, then soared by 141.73% to $30.8 million in 2022, then skyrocketed by 35.36% to $41.7 million in 2023, then surged by 50.73% to $62.8 million in 2024, then fell by 1.59% to $61.8 million in 2025.
  • Business Quant data shows EBIT for CPRX at $61.8 million in Q4 2025, $66.3 million in Q3 2025, and $66.3 million in Q2 2025.